M. Keskinkiliç Et Al. , "The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment," ANNALS OF ONCOLOGY , vol.8, pp.101223, 2023
Keskinkiliç, M. Et Al. 2023. The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment. ANNALS OF ONCOLOGY , vol.8 , 101223.
Keskinkiliç, M., Semiz, H. S., Yavuzşen, T., & Öztop, I., (2023). The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment. ANNALS OF ONCOLOGY , vol.8, 101223.
Keskinkiliç, MERVE Et Al. "The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment," ANNALS OF ONCOLOGY , vol.8, 101223, 2023
Keskinkiliç, MERVE Et Al. "The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment." ANNALS OF ONCOLOGY , vol.8, pp.101223, 2023
Keskinkiliç, M. Et Al. (2023) . "The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment." ANNALS OF ONCOLOGY , vol.8, p.101223.
@article{article, author={MERVE KESKİNKILIÇ Et Al. }, title={The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment}, journal={ANNALS OF ONCOLOGY}, year=2023, pages={101223} }